Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes

• Status: Completed
• Trial end date: 2016-02-28
• Target enrollment: 0
• Participant gender: All

Summary

The present study assessed the therapeutic effect of exenatide and metformin as the initial therapy in overweight/obese patients with newly diagnosed Type 2 diabetes (T2D).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Chao Yang Hospital
• Treatments: Exenatide; Metformin

Criteria

Inclusion Criteria:

• age 20 - <65 years,

• body mass index (BMI) ≥ 24 kg/m2,

• HbA1c ≥ 7% (53mmol/mol).

• diabetes antibodies (-)

• diagnosed with T2D within the previous 3 months

Exclusion Criteria:

• anti-diabetic drugs or diet therapy before participation

• pancreatitis

• coronary artery disease

• liver function impairment

• renal function impairment

• intestinal surgery

• chronic hypoxic diseases (emphysema and cor pulmonale)

• infectious disease

• hematological disease

• systemic inflammatory disease

• cancer

• pregnant, possibly pregnant

• ingesting agents known to influence glucose or lipid metabolism